Abbott launches next gen CGM device FreeStyle Libre 2 Plus in India

Abbott

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Healthcare major Abbott has launched its next-generation continuous glucose monitoring (CGM) device, the FreeStyle Libre 2 Plus, in India, offering real-time glucose readings every minute and optional alarms to alert users of high or low sugar levels.

The company didn't disclose the price of the device.

The launch marks a significant upgrade to Abbott’s FreeStyle Libre portfolio, which is already used by over 7 million people across 60 countries. The new sensor transmits glucose data directly to a smartphone without requiring manual scans, and can be worn for up to 15 days. It also integrates with Abbott’s digital health ecosystem, including LibreView and LibreLinkUp, allowing caregivers and healthcare professionals to monitor patients remotely.

“With 101 million people living with diabetes, India is the second-largest diabetes population globally,” said Dr. Kenneth Lee, Regional Medical Affairs Director, Asia Pacific, Diabetes Division, Abbott. “FreeStyle Libre 2 Plus empowers people to manage their condition better, with robust accuracy and the freedom to avoid routine fingersticks.”

Clinical studies cited by Abbott show that Libre technology can reduce hypoglycemia episodes by up to 43%, lower HbA1c levels by up to 1.5%, and cut hospital visits by 66%. It has also been linked to a 78% reduction in cardiovascular complications and a 44% drop in stroke-related hospitalizations among insulin-treated patients.

The device is now available across India for adults and children aged two and above, including pregnant women with gestational diabetes.

Abbott’s move comes amid growing demand for real-time, accessible diabetes management tools in India, where CGM adoption is rising and digital health integration is gaining traction.